Clincosm LogoSign in Get a demo

major depressive disorder

Showing NaN - NaN of 86
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDD Trial in United States (REL-1017)

Recruiting
  • Major Depressive Disorder
  • Saraland, Alabama
  • +102 more
Jan 18, 2023

MDD Trial in United States (SAGE-217, Placebo)

Completed
Has Results
  • Major Depressive Disorder
  • Rogers, Arkansas
  • +52 more
Nov 22, 2022

Migraine, MDD Trial in Worldwide (Fremanezumab, Placebo)

Completed
  • Migraine
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +63 more
Dec 7, 2022

MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)

Completed
Has Results
  • Major Depressive Disorder
  • +2 more
  • AXS-05 (dextromethorphan and bupropion) oral tablets
  • Phoenix, Arizona
  • +50 more
Sep 16, 2022

MDD Trial in Australia, United States (10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114)

Completed
  • Major Depressive Disorder
  • 10 mg PRAX-114
  • +4 more
  • Lafayette, California
  • +23 more
Aug 18, 2022

MDD Trial in Australia, United States (PRAX-114, Placebo)

Completed
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +30 more
Jul 20, 2022

Treatment Resistant Depression, MDD Trial in United States (AXS-05, Placebo)

Completed
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +19 more
Jul 8, 2022

Anhedonia, MDD Trial in Puerto Rico, United States (Placebo, NBI-1065846)

Recruiting
  • Anhedonia
  • Major Depressive Disorder
  • Birmingham, Alabama
  • +11 more
Jun 27, 2022

Treatment Resistant Depression, MDD Trial in United States (AXS-05 (dextromethorphan-bupropion))

Completed
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • AXS-05 (dextromethorphan-bupropion)
  • Little Rock, Arkansas
  • +19 more
Jun 2, 2022

MDD Trial in United States (SP-624, Placebo)

Active, not recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +38 more
May 13, 2022

MDD Trial in United States (REL-1017, Placebo)

Recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +57 more
May 9, 2022

MDD Trial in United States (REL-1017, Placebo)

Recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +52 more
Apr 14, 2022

MDD Trial in Worldwide (Lumateperone, Placebo)

Recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +27 more
Apr 7, 2022

MDD Trial in Worldwide (Lumateperone)

Enrolling by invitation
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +44 more
Apr 7, 2022

MDD Trial in United States (BTRX-335140, Placebo)

Active, not recruiting
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +37 more
Mar 11, 2022

MDD Trial in United States (Levomilnacipran ER, Fluoxetine, Placebo)

Completed
Has Results
  • Major Depressive Disorder
  • Levomilnacipran ER
  • +2 more
  • Little Rock, Arkansas
  • +50 more
Mar 1, 2022

MDD Trial in United States (SAGE-217, Placebo)

Terminated
  • Major Depressive Disorder
  • Bentonville, Arkansas
  • +45 more
Oct 15, 2021

Depression, MDD Trial in United States (AXS-05, Placebo)

Completed
  • Depression
  • Major Depressive Disorder
  • Phoenix, Arizona
  • +42 more
Sep 22, 2021

MDD Trial in United States (AXS-05, Bupropion)

Completed
Has Results
  • Major Depressive Disorder
  • Beverly Hills, California
  • +3 more
Sep 22, 2021

MDD Trial in Worldwide (SPD489 (Lisdexamfetamine dimesylate) + Antidepressant)

Terminated
Has Results
  • Major Depressive Disorder
  • SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
  • Birmingham, Alabama
  • +211 more
Jun 9, 2021

MDD Trial in United States (Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + )

Completed
Has Results
  • Major Depressive Disorder
  • Antidepressant + SPD489 (lisdexamfetamine dimesylate)
  • Antidepressant + placebo
  • Newport Beach, California
  • +14 more
Jun 8, 2021

MDD Trial in Worldwide (Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine

Completed
Has Results
  • Major Depressive Disorder
  • Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
  • +4 more
  • Little Rock, Arkansas
  • +81 more
May 25, 2021

MDD Trial in United States (BTRX-246040 oral capsule(s), Placebo oral capsule(s))

Completed
Has Results
  • Major Depressive Disorder
  • BTRX-246040 oral capsule(s)
  • Placebo oral capsule(s)
  • Cerritos, California
  • +7 more
Apr 19, 2021

MDD Trial in United States (CP-601,927, Placebo)

Terminated
Has Results
  • Major Depressive Disorder
  • Little Rock, Arkansas
  • +57 more
Apr 7, 2021

MDD Trial in Australia, Puerto Rico, United States (ALKS 5461, ALKS 5461 Placebo)

Completed
Has Results
  • Major Depressive Disorder
  • ALKS 5461
  • ALKS 5461 Placebo
  • Tucson, Arizona
  • +34 more
Mar 15, 2021